<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019721</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067051</org_study_id>
    <secondary_id>NCI-99-C-0092</secondary_id>
    <secondary_id>NCI-T99-0033</secondary_id>
    <nct_id>NCT00019721</nct_id>
    <nct_alias>NCT00001808</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Immunization of Patients With Metastatic Melanoma Using MART-1 and GP100 Peptides Modified to Increase Binding to HLA-0201</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining&#xD;
      vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma.&#xD;
&#xD;
      PURPOSE: Phase II trial to compare the effectiveness of vaccine therapy with or without&#xD;
      interleukin-2 in treating patients who have metastatic melanoma that has not responded to&#xD;
      previous therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of gp100:209-217(210M) peptide and MART-1:26-35(27L) peptide&#xD;
           administered with or without high-dose interleukin-2 (IL-2) in patients with metastatic&#xD;
           melanoma who are HLA-A0201 positive.&#xD;
&#xD;
        -  Determine the efficacy of these peptides in patients who cannot receive IL-2.&#xD;
&#xD;
        -  Compare the efficacy of IL-2 with or without these peptides in patients who need&#xD;
           immediate treatment with IL-2.&#xD;
&#xD;
        -  Determine the efficacy of MART-1:26-35(27L) peptide in patients who have received prior&#xD;
           gp100 antigen.&#xD;
&#xD;
        -  Compare the immunologic response experienced by patients who have received peptide, with&#xD;
           or without IL-2, as measured by changes in T-cell precursors from before to after&#xD;
           treatment.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a partially randomized study.&#xD;
&#xD;
      Patients are assigned to 1 of 4 treatment groups based on disease status and prior therapy.&#xD;
&#xD;
        -  Group A (eligible to receive interleukin-2 (IL-2) but not in immediate need; no prior&#xD;
           immunization with gp100 or MART-1 antigen): Patients are randomized to 1 of 2 treatment&#xD;
           arms.&#xD;
&#xD;
             -  Arm I: Patients receive gp100 and MART-1 peptides emulsified in Montanide ISA-51&#xD;
                (ISA-51) subcutaneously (SC) on day 1. (Arm I closed as of 10/30/02).&#xD;
&#xD;
             -  Arm II: Patients receive both peptides as in arm I on day 1 and high-dose IL-2 IV&#xD;
                over 15 minutes every 8 hours on days 2-5 (for up to 12 doses). (Arm II closed as&#xD;
                of 10/30/02).&#xD;
&#xD;
        -  Group B (ineligible to receive IL-2 due to other debilitating disease): Patients receive&#xD;
           treatment as in group A, arm I.&#xD;
&#xD;
        -  Group C (need immediate IL-2 therapy due to extensive and rapid progression of disease):&#xD;
           Patients receive treatment as in group A, arm II. (Group C closed as of 10/30/02).&#xD;
&#xD;
        -  Group D (prior immunization with gp100 antigen): Patients receive modified&#xD;
           MART-1:26-35(27L) peptide emulsified in ISA-51 SC on day 1.&#xD;
&#xD;
      Treatment in all groups repeats every 3 weeks for 4 courses. Patients who achieve a minor,&#xD;
      mixed, or partial response may receive up to 12 additional courses. Patients who achieve&#xD;
      complete response receive 2 additional courses.&#xD;
&#xD;
      Patients are followed at 4-6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 103 patients (15-25 for group A, arm I; 19-33 for group A, arm&#xD;
      II; and 15 each for groups B, C, and D) will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma that has failed standard therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  HLA-A0201 positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  AST/ALT less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular disease&#xD;
&#xD;
          -  If cardiovascular disease or other debilitating symptoms present, may receive peptide&#xD;
             emulsified with Montanide ISA-51 only&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major respiratory disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No autoimmune disease or immunodeficiency disease&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy&#xD;
&#xD;
          -  No prior MART-1 antigen immunization&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

